Assessment of D-dimer and CRP for Cardiovascular Risk Prediction in Hemodialysis Patients
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: C-Reactive Protein (CRP) Test, D-dimer Test, Electrocardiogram (ECG).
- Who it may be relevant to
- Registry conditions: End Stage Renal Disease on Dialysis. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Egypt
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Assessment of Blood Biomarkers (D-dimer and C-Reactive Protein) in Predicting Cardiovascular Complications Among Hemodialysis Patients: A Cross-Sectional Study
Overview
This study aims to assess whether two blood markers - C-reactive protein (CRP) and D-dimer - can help predict cardiovascular complications in patients undergoing regular hemodialysis. Cardiovascular disease is a common and serious problem in dialysis patients, and early detection is important. the study will include 100 adult patients from the Hemodialysis Unit at Assiut University Hospital. Participants will be divided into two groups: those with and those without known heart disease. Each participant will have a one-time blood test to measure CRP and D-dimer levels. In addition, an electrocardiogram (ECG) will be done once to check for signs of heart problems.
Detailed description
This cross-sectional study is designed to explore the potential role of hematologic biomarkers in predicting cardiovascular complications among patients undergoing maintenance hemodialysis. Cardiovascular disease is a leading cause of morbidity and mortality in this population, and systemic inflammation and hypercoagulability are thought to contribute significantly to adverse outcomes.
C-reactive protein (CRP) is a well-established marker of systemic inflammation, while D-dimer reflects activation of the coagulation and fibrinolytic pathways. Both biomarkers have been associated with increased cardiovascular risk in the general population, but their predictive value in hemodialysis patients remains insufficiently characterized.
A total of 100 adult patients on maintenance hemodialysis will be evaluated. The population will be stratified into two groups based on the presence or absence of clinically confirmed cardiovascular disease. Laboratory analysis will include measurement of CRP and D-dimer, and cardiovascular assessment will include a standard 12-lead ECG. Clinical and demographic data will also be collected.
Interventions
- Diagnostic test C-Reactive Protein (CRP) Test
Blood samples will be collected once from all participants to measure CRP levels - Diagnostic test D-dimer Test
D-dimer levels will be assessed once to evaluate thrombotic risk. - Diagnostic test Electrocardiogram (ECG)
A standard 12-lead ECG will be performed once per participant to assess cardiovascular status
Primary outcome measures
- Serum CRP level among hemodialysis patients [Time frame: At baseline (one-time measurement)]
- Plasma D-dimer level among hemodialysis patients [Time frame: At baseline (one-time measurement)]
Secondary outcome measures (1)
- Presence of cardiovascular abnormalities on ECG [Time frame: At baseline (one-time measurement)]
Eligibility criteria
Inclusion criteria
- Adults aged ≥18 years
On regular hemodialysis for at least 3 months
Able and willing to provide informed consent
Group I: Hemodialysis patients with no clinically documented cardiovascular disease
Group II: Hemodialysis patients with confirmed cardiovascular disease (by medical records, ECGs, echocardiography, or documented hospital admissions)
Exclusion criteria
- Acute or recent infection (within the past 4 weeks)
Use of anticoagulant or antiplatelet therapy
Active malignancy
Autoimmune or chronic inflammatory disease
Known bleeding or thrombotic disorders
Pregnancy
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
Egypt · 1 center
- Assiut University Hospital — Asyut
Identifiers
NCT: NCT07130721 · 04-2025-201318